Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy

Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies o...

Descripción completa

Detalles Bibliográficos
Autores: Kamali, Ali N., Hamedifar, Haleh, Eisenhut, Michael, Bautista Santa Cruz, José Manuel
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/110371
Acceso en línea:https://hdl.handle.net/20.500.14352/110371
Access Level:acceso abierto
Palabra clave:579.61
Multiple myeloma
Check point inhibitors
Immunotherapy
Microbiología (Biología)
3201.03 Microbiología Clínica
id ES_0658fcde91b449fc446e3f55d0dbc8fe
oai_identifier_str oai:docta.ucm.es:20.500.14352/110371
network_acronym_str ES
network_name_str España
repository_id_str
spelling Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapyKamali, Ali N.Hamedifar, HalehEisenhut, MichaelBautista Santa Cruz, José Manuel579.61Multiple myelomaCheck point inhibitorsImmunotherapyMicrobiología (Biología)3201.03 Microbiología ClínicaMultiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies of immune checkpoint inhibitor therapy, either alone or in combination with anticancer drugs, showed excessive side effects or low efficacy, particularly in advanced MM patients. In this context, lymphocyte levels of exhaustion markers play a pivotal role in the MM tumor microenvironment (TME). Hence in the present review, the mechanisms relevant to MM of five inhibitory molecules including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin, and mucin domain 3 (Tim-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig Suppressor of T-cell activation and killer immunoglobulin-like receptors along with bispecific T-cell antibodies (BsAbs) will be discussed. Further, we summarized the underlying biology of these checkpoints in cancer and their rapidly emerging role in pathways in MM along with presenting recent clinical trials in context.SAGE Publications LtdUniversidad Complutense de Madrid20242024-01-0120242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/110371reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1103712026-06-02T12:44:21Z
dc.title.none.fl_str_mv Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
title Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
spellingShingle Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
Kamali, Ali N.
579.61
Multiple myeloma
Check point inhibitors
Immunotherapy
Microbiología (Biología)
3201.03 Microbiología Clínica
title_short Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
title_full Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
title_fullStr Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
title_full_unstemmed Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
title_sort Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
dc.creator.none.fl_str_mv Kamali, Ali N.
Hamedifar, Haleh
Eisenhut, Michael
Bautista Santa Cruz, José Manuel
author Kamali, Ali N.
author_facet Kamali, Ali N.
Hamedifar, Haleh
Eisenhut, Michael
Bautista Santa Cruz, José Manuel
author_role author
author2 Hamedifar, Haleh
Eisenhut, Michael
Bautista Santa Cruz, José Manuel
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 579.61
Multiple myeloma
Check point inhibitors
Immunotherapy
Microbiología (Biología)
3201.03 Microbiología Clínica
topic 579.61
Multiple myeloma
Check point inhibitors
Immunotherapy
Microbiología (Biología)
3201.03 Microbiología Clínica
description Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies of immune checkpoint inhibitor therapy, either alone or in combination with anticancer drugs, showed excessive side effects or low efficacy, particularly in advanced MM patients. In this context, lymphocyte levels of exhaustion markers play a pivotal role in the MM tumor microenvironment (TME). Hence in the present review, the mechanisms relevant to MM of five inhibitory molecules including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin, and mucin domain 3 (Tim-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig Suppressor of T-cell activation and killer immunoglobulin-like receptors along with bispecific T-cell antibodies (BsAbs) will be discussed. Further, we summarized the underlying biology of these checkpoints in cancer and their rapidly emerging role in pathways in MM along with presenting recent clinical trials in context.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/110371
url https://hdl.handle.net/20.500.14352/110371
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications Ltd
publisher.none.fl_str_mv SAGE Publications Ltd
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402912461946880
score 15.811543

Similares en LA Referencia